We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANRO icon
276
Alto Neuroscience
ANRO
$1.21B
$402K 0.09%
+15,239
New +$352K
PCVX icon
277
Vaxcyte
PCVX
$8.88B
$401K 0.09%
6,894
+768
+13% +$41.7K
SION
278
Sionna Therapeutics
SION
$324M
$401K 0.09%
9,109
+2,735
+43% +$109K
DYN icon
279
Dyne Therapeutics
DYN
$3.3B
$400K 0.09%
17,988
+3,838
+27% +$71.4K
IMMX icon
280
Immix Biopharma
IMMX
$880M
$399K 0.09%
+38,721
New +$359K
RVMD icon
281
Revolution Medicines
RVMD
$42.7B
$398K 0.09%
2,127
-1,327
-38% -$194K
ANNX icon
282
Annexon
ANNX
$751M
$397K 0.09%
69,468
+14,602
+27% +$80.7K
SGP
283
SpyGlass Pharma
SGP
$963M
$395K 0.09%
+17,744
New +$385K
BBDC icon
284
Barings BDC
BBDC
$917M
$394K 0.09%
46,262
-9,729
-17% -$83.6K
ANAB icon
285
AnaptysBio
ANAB
$1.6B
$394K 0.09%
5,835
-232
-4% -$14.1K
CADL icon
286
Candel Therapeutics
CADL
$852M
$394K 0.09%
+38,224
New +$289K
ASMB icon
287
Assembly Biosciences
ASMB
$531M
$392K 0.09%
14,251
+6,698
+89% +$182K
FCT
288
DELISTED
First Trust Senior Floating Rate Income Fund II
FCT
$391K 0.09%
40,444
-11,101
-22% -$107K
EVF
289
Eaton Vance Senior Income Trust
EVF
$88.5M
$390K 0.09%
78,410
-20,455
-21% -$102K
CGON icon
290
CG Oncology
CGON
$6.49B
$390K 0.09%
5,493
-1,167
-18% -$76.3K
TSHA icon
291
Taysha Gene Therapies
TSHA
$1.64B
$390K 0.09%
57,303
+10,208
+22% +$60.4K
CLDX icon
292
Celldex Therapeutics
CLDX
$3.03B
$389K 0.09%
10,464
+553
+6% +$17.9K
DNTH icon
293
Dianthus Therapeutics
DNTH
$5.81B
$389K 0.09%
3,987
-2,485
-38% -$217K
PRTA icon
294
Prothena Corp
PRTA
$422M
$388K 0.09%
39,660
+13,340
+51% +$132K
GLAD icon
295
Gladstone Capital
GLAD
$437M
$388K 0.09%
19,977
-8,432
-30% -$160K
DSU icon
296
BlackRock Debt Strategies Fund
DSU
$590M
$387K 0.09%
39,931
-11,571
-22% -$113K
VIR icon
297
Vir Biotechnology
VIR
$1.76B
$387K 0.09%
38,002
-2,757
-7% -$26.2K
TYRA icon
298
Tyra Biosciences
TYRA
$1.52B
$387K 0.09%
12,123
+74
+0.6% +$2.45K
ACHV icon
299
Achieve Life Sciences
ACHV
$775M
$387K 0.09%
+59,275
New +$283K
BEAM icon
300
Beam Therapeutics
BEAM
$2.4B
$387K 0.09%
11,272
+1,306
+13% +$39.4K
10 11
12
13 14

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.